Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : La Jolla Diagnostics, Inc.(OTC BB: LAJD) -- Ignore unavailable to you. Want to Upgrade?

To: Evelio Fernandez who wrote (87)	12/1/1998 10:55:00 AM
From: jeffrey rainey	Read Replies (1) \| Respond to of 168

La Jolla Diagnostics Inc. Prepares HIV Test For Mass Distribution In Sub-Saharan Africa Business Editors/Health and Medical Writers LA JOLLA, Calif.--(BW HealthWire)--Dec. 1, 1998--La Jolla Diagnostics Inc. (OTC BB:LAJD) announced today that its subsidiary DiagnosTech Inc. has developed a rapid diagnostic test for HIV I & II for mass distribution in Sub-Saharan Africa. According to a joint United Nations, World Health Organization report, approximately 34 million people worldwide are infected with HIV. Two thirds of them are in Sub-Saharan Africa, including 70 percent of the new cases reported in 1998. The majority of the newly infected are young people under the age of 24. Political turmoil, poverty, the scarcity of medical facilities and the lack of early symptoms keep many people from finding out that they are infected with the HIV virus. DiagnosTech Inc. has designed a special rapid diagnostic HIV test which is particularly suited for the environmental conditions found in Africa, because it is easy to use, and maintains its sensitivity even when subjected to extreme changes in temperature and humidity. A large African marketing firm has made a sample purchase of the product and plans to place a bulk order during the first quarter of 1999 for wide distribution in a manner which will make it readily accessible to major populations. La Jolla Diagnostics is an emerging company engaged in the development and marketing of state-of-the-art diagnostic tests (including a proprietary test for active tuberculosis), health care products and nutraceuticals. The health care and nutraceutical products, including a treatment from migraine headaches, are formulated using a patented clustered water technology. US Patent 5711950. --30--jm/sd* sf/sd CONTACT: La Jolla Diagnostics Inc. 800/454-6790, Fax 619/454-7851 lajd.com lajd96@aol.com